Fig. 3: Relapse-free survival (RFS) and subgroup analysis. | Nature Communications

Fig. 3: Relapse-free survival (RFS) and subgroup analysis.

From: Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia

Fig. 3

a The RFS in all patients who received infusion, the median RFS was 319.0 days (95% CI: 182.6–455.4). The rate of RFS at 1 year was 45.0% (95% CI: 26.8–63.2). b The RFS between pediatric and adult cohort, no significant difference observed (p = 0.168). c The RFS in patients with the 2 subtypes of EMDs (CNS involvement only or EMDs other than CNS) were lower than that in patients without EMDs (p = 0.015 and 0.003), respectively, but no significant difference existed between the subtypes (p = 0.961). d The RFS in patients with or without higher Tregs before infusion, 1-year RFS rate was 11.9% vs. 56.7% (p = 0.002). e The RFS in patients with or without high-risk cytogenetic factors, 1-year RFS rate was 24.2% vs. 67.7% (p = 0.034). Patients who were bridged to allo-HSCT were excluded when we analyzed the influence of patient characteristics on RFS (c–e). b–e were performed by the Kaplan-Meier approach and used a two-sided log-rank test. Source data is provided as a Source Data file or available at https://doi.org/10.6084/m9.figshare.13136078.v1.

Back to article page